← Back to Screener
Medifast, Inc. (MED)
Price$10.92
Favorite Metrics
Price vs S&P 500 (26W)-26.15%
Price vs S&P 500 (4W)0.11%
Market Capitalization$121.02M
Indicated Dividend Yield (Annual)9.97%
All Metrics
P/CF (Annual)17.63x
Book Value / Share (Quarterly)$18.10
P/TBV (Annual)4.53x
Revenue Growth (3Y)-37.74%
Cash Flow / Share (Quarterly)$0.11
Payout Ratio (TTM)0.06%
Price vs S&P 500 (YTD)-1.52%
Gross Margin (TTM)71.33%
Net Profit Margin (TTM)-4.84%
EPS (TTM)$-1.70
10-Day Avg Trading Volume0.24M
EPS Excl Extra (TTM)$-1.70
Revenue Growth (5Y)-16.22%
EPS (Annual)$-1.70
Dividend / Share (Annual)$0.02
ROI (Annual)-9.39%
Gross Margin (Annual)71.33%
Net Profit Margin (5Y Avg)4.90%
Cash / Share (Quarterly)$15.22
Revenue Growth QoQ (YoY)-36.90%
ROA (Last FY)-7.53%
Revenue Growth TTM (YoY)-35.96%
EBITD / Share (TTM)$0.23
ROE (5Y Avg)42.92%
Operating Margin (TTM)-3.68%
Cash Flow / Share (Annual)$0.11
P/B Ratio0.61x
P/B Ratio (Quarterly)0.59x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.08x
Net Interest Coverage (TTM)264.00x
ROA (TTM)-7.01%
EV / EBITDA (TTM)12.75x
EPS Incl Extra (Annual)$-1.70
Current Ratio (Annual)4.69x
Quick Ratio (Quarterly)3.89x
3-Month Avg Trading Volume0.27M
52-Week Price Return-9.79%
EV / Free Cash Flow (Annual)25.39x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$8.01
P/S Ratio (Annual)0.31x
Asset Turnover (Annual)1.56x
52-Week High$15.46
Operating Margin (5Y Avg)6.86%
EPS Excl Extra (Annual)$-1.70
CapEx CAGR (5Y)-0.99%
Tangible BV CAGR (5Y)29.31%
26-Week Price Return-17.41%
Quick Ratio (Annual)3.89x
13-Week Price Return-6.16%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.69x
Enterprise Value$31.715
Revenue / Share Growth (5Y)-14.87%
Asset Turnover (TTM)1.45x
Book Value / Share Growth (5Y)6.31%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)3.53x
Pretax Margin (Annual)-1.46%
Cash / Share (Annual)$15.22
3-Month Return Std Dev35.16%
Gross Margin (5Y Avg)72.55%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)-53.46%
ROE (Last FY)-9.39%
Net Interest Coverage (Annual)203.67x
EPS Basic Excl Extra (Annual)$-1.70
P/FCF (TTM)9.58x
Receivables Turnover (TTM)4388.40x
EV / Free Cash Flow (TTM)25.39x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.70
Receivables Turnover (Annual)934.80x
ROI (TTM)-8.89%
Dividend Growth Rate (5Y)-66.94%
P/S Ratio (TTM)0.31x
Pretax Margin (5Y Avg)7.37%
Revenue / Share (Annual)$35.13
Tangible BV / Share (Annual)$6.55
Free OCF CAGR (5Y)-61.05%
Price vs S&P 500 (52W)-44.89%
Year-to-Date Return2.62%
5-Day Price Return3.10%
EPS Normalized (Annual)$-1.70
ROA (5Y Avg)22.37%
Net Profit Margin (Annual)-4.84%
Month-to-Date Return7.56%
Cash Flow / Share (TTM)$12.12
EBITD / Share (Annual)$0.28
Operating Margin (Annual)-3.68%
LT Debt / Equity (Annual)0.03x
P/CF (TTM)17.63x
ROI (5Y Avg)42.92%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.70
P/TBV (Quarterly)3.35x
Payout Ratio (Annual)34.19%
P/B Ratio (Annual)0.59x
Dividend / Share (TTM)$0.02
Inventory Turnover (TTM)3.53x
Pretax Margin (TTM)-1.46%
Book Value / Share (Annual)$18.10
Price vs S&P 500 (13W)-9.03%
Dividend Yield (TTM)0.16%
Beta0.59x
P/FCF (Annual)96.89x
Revenue / Share (TTM)$35.09
ROE (TTM)-8.89%
52-Week Low$9.22
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.33
2.33
2.33
2.33
Industry Peers — Miscellaneous Food Products(5)
| Symbol | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|
MEDMedifast, Inc. | — | -8.89% | -16.22% | 9.97% | $10.92 |
MKCMcCormick & Company, Incorporated Non-VTG CS | 17.97x | 27.31% | 4.08% | 3.53% | $52.85 |
MKC.VMcCormick & Company, Incorporated Voting CS | 17.97x | 27.31% | 4.08% | 3.63% | $52.75 |
UTZUtz Brands, Inc. | 1360.52x | 0.11% | 8.33% | 3.33% | $7.62 |
FARMFarmer Bros Co | — | -47.58% | -7.35% | — | $1.25 |
JVACoffee Holding Co., Inc. | 18.63x | 6.84% | 7.85% | 1.74% | $4.63 |
About
Medifast Inc provides obesity and weight management solutions through OPTAVIA, a coach-guided platform combining personalized nutrition, behavioral coaching, and community support. The company offers access to GLP-1 medications where clinically appropriate to complement its core lifestyle program. OPTAVIA's model focuses on habit-based change and long-term health outcomes, positioning the company in the growing weight management market.